Scale development study demonstrates initial validity of the Lung Cancer Stigma Inventory in lung cancer patients, suggesting an effective tool to quantify disease-related stigma.
INTRODUCTION: Among patients with lung cancer, stigma is associated with negative psychosocial and behavioral outcomes. There is a need to develop psychometrically robust patient-reported outcome (PRO) measures for stigma that incorporate perspectives of patients diagnosed with lung cancer. As part of our multi-phase process of measure development and validation, we report on scale formation and preliminary psychometric evaluation of the Lung Cancer Stigma Inventory (LCSI). METHOD: =20) feedback. Phase III focused on initial psychometric scale evaluation in a unique sample of 231 lung cancer patients. RESULTS: = 0.58, p< 0.001). DISCUSSION: (LCSI). Subsequent work will be conducted to establish further evidence of validity and clinically meaningful change.
No takes yet. Share an insight, caveat, or question.
Hamann et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: